Theralase(R) Lists Warrants on the TSXV

Executive Summary

• TSX Venture Exchange has accepted up to 20,399,050 common share purchase warrants for listing and trading.
• Warrant trading is expected to commence on June 9, 2026, under the symbol "TLT.WT".
• The warrants were issued as part of a brokered private placement that closed on May 20, 2026, raising C$4.6 million in aggregate gross proceeds.

Key Details

• Warrant Listing & Trading: TSXV accepted up to 20,399,050 warrants (CUSIP: 88337V142) for trading; expected to begin at market open on June 9, 2026, under symbol "TLT.WT".
• Private Placement Structure: Closed May 20, 2026; issued 19,166,667 units at C$0.24 per unit.
• Agent Compensation: 1,232,383 non-transferrable compensation options granted to Research Capital Corporation, exercisable at C$0.24 per unit until May 20, 2031.
• Gross Proceeds: C$4,600,000 raised, including the full exercise of the agent's over-allotment option.
• Warrant Terms: Each warrant entitles the holder to purchase one common share at an exercise price of C$0.32 per share, exercisable until May 20, 2031.
• Governing Documentation: Warrants are governed by a Warrant Indenture dated May 20, 2026, with TSX Trust Company of Canada serving as Warrant Agent.
• Reference: Full details of the underlying private placement are available in the Company's news release dated May 20, 2026, filed on SEDAR+.